Using this discovery, we further disclosed that the anti-myeloma activity of IMiDs can be augmented by inhibiting the CASP-8 activation and suggests a potential new combination therapy that might benefit myeloma patients. The gene discussed is CASP8; the disease is plasma cell myeloma.